Basilea Pharmaceutica AG (BPMUF)
USD 52.83
(0.0%)
USD 52.83
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 68.7 Million CHF | -32.93% |
| 2022 | 102.43 Million CHF | -38.01% |
| 2021 | 165.25 Million CHF | -9.01% |
| 2020 | 181.61 Million CHF | 104.66% |
| 2019 | 88.74 Million CHF | -44.07% |
| 2018 | 158.67 Million CHF | 8.61% |
| 2017 | 146.1 Million CHF | 432.05% |
| 2016 | -44 Million CHF | 62.71% |
| 2015 | -118 Million CHF | 24.42% |
| 2014 | -156.12 Million CHF | -31.31% |
| 2013 | -118.89 Million CHF | 46.91% |
| 2012 | -223.95 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 42.97 Million CHF | 0.0% |
| 2023 Q1 | 80 Million CHF | -21.9% |
| 2023 Q2 | 82.06 Million CHF | 2.58% |
| 2023 Q3 | 66.61 Million CHF | -18.83% |
| 2023 Q4 | 68.7 Million CHF | 3.15% |
| 2023 FY | 68.7 Million CHF | -32.93% |
| 2022 Q1 | 183.43 Million CHF | 11.85% |
| 2022 Q3 | 100.49 Million CHF | -45.52% |
| 2022 Q4 | 102.43 Million CHF | 1.94% |
| 2022 FY | 102.43 Million CHF | -38.01% |
| 2022 Q2 | 184.44 Million CHF | 0.55% |
| 2021 Q3 | 164.35 Million CHF | 13.37% |
| 2021 Q1 | 145.1 Million CHF | -22.28% |
| 2021 FY | 165.25 Million CHF | -9.01% |
| 2021 Q2 | 144.97 Million CHF | -0.09% |
| 2021 Q4 | 164 Million CHF | -0.22% |
| 2020 Q3 | 179.81 Million CHF | 30.04% |
| 2020 Q4 | 186.7 Million CHF | 3.83% |
| 2020 Q1 | 139.33 Million CHF | -2.71% |
| 2020 FY | 181.61 Million CHF | 104.66% |
| 2020 Q2 | 138.27 Million CHF | -0.77% |
| 2019 Q2 | 69 Million CHF | -0.7% |
| 2019 Q4 | 143.22 Million CHF | 60.45% |
| 2019 Q1 | 69.48 Million CHF | 190.16% |
| 2019 Q3 | 89.26 Million CHF | 29.37% |
| 2019 FY | 88.74 Million CHF | -44.07% |
| 2018 FY | 158.67 Million CHF | 8.61% |
| 2018 Q4 | 23.94 Million CHF | 0.0% |
| 2018 Q3 | 23.94 Million CHF | -59.62% |
| 2018 Q2 | 59.31 Million CHF | 0.0% |
| 2018 Q1 | 59.31 Million CHF | 1418.04% |
| 2017 Q2 | 52.74 Million CHF | 0.0% |
| 2017 FY | 146.1 Million CHF | 432.05% |
| 2017 Q4 | -4.5 Million CHF | 0.0% |
| 2017 Q3 | -4.5 Million CHF | -108.53% |
| 2017 Q1 | 52.74 Million CHF | 221.07% |
| 2016 Q3 | -43.56 Million CHF | 33.83% |
| 2016 FY | -44 Million CHF | 62.71% |
| 2016 Q2 | -65.83 Million CHF | 0.0% |
| 2016 Q1 | -65.83 Million CHF | 44.38% |
| 2016 Q4 | -43.56 Million CHF | 0.0% |
| 2015 FY | -118 Million CHF | 24.42% |
| 2015 Q4 | -118.35 Million CHF | 0.0% |
| 2015 Q3 | -118.35 Million CHF | 13.54% |
| 2015 Q1 | -136.88 Million CHF | 12.32% |
| 2015 Q2 | -136.88 Million CHF | 0.0% |
| 2014 Q1 | -130.88 Million CHF | -10.08% |
| 2014 Q3 | -156.12 Million CHF | -19.28% |
| 2014 Q2 | -130.88 Million CHF | 0.0% |
| 2014 FY | -156.12 Million CHF | -31.31% |
| 2014 Q4 | -156.12 Million CHF | 0.0% |
| 2013 FY | -118.89 Million CHF | 46.91% |
| 2013 Q1 | -142.75 Million CHF | 36.26% |
| 2013 Q2 | -142.75 Million CHF | 0.0% |
| 2013 Q3 | -118.89 Million CHF | 16.71% |
| 2013 Q4 | -118.89 Million CHF | 0.0% |
| 2012 Q4 | -223.95 Million CHF | 0.0% |
| 2012 Q3 | -223.95 Million CHF | 0.0% |
| 2012 FY | -223.95 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -335.869% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1568.422% |
| SQZ Biotechnologies Company | -36.23 Million USD | 289.597% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -60.554% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 1189.789% |
| Mesoblast Limited | 55.85 Million USD | -23.001% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -7310.164% |
| Genus plc | 190.6 Million USD | 63.953% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -2972.95% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -5559.995% |
| Marizyme, Inc. | 18.56 Million USD | -270.003% |
| ContraFect Corporation | -6.02 Million USD | 1240.159% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -10003.824% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -50929.791% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -5846.363% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -2964.178% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -1148.77% |
| MultiCell Technologies, Inc. | 90.04 USD | -76305986.184% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 9460.771% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -430.712% |
| EV Biologics, Inc. | 1.36 Million USD | -4922.475% |
| Q BioMed Inc. | 4.06 Million USD | -1592.263% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -124.867% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -10939.52% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -6717.992% |
| Biomind Labs Inc. | 711.4 Thousand USD | -9557.831% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 37.429% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -436.489% |
| Skye Bioscience, Inc. | -5.72 Million USD | 1300.862% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -7886.832% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -49044.517% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -1116.386% |
| IMV Inc. | 7.67 Million USD | -795.715% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -345729.768% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -3020.19% |
| GB Sciences, Inc. | 1.74 Million USD | -3832.088% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 37483.289% |
| HST Global, Inc. | 96.79 Thousand USD | -70882.406% |
| CSL Limited | 10.52 Billion USD | 99.347% |
| Halberd Corporation | 144.72 Thousand USD | -47374.796% |
| Enzolytics Inc. | 981.65 Thousand USD | -6898.989% |
| Resverlogix Corp. | 6.45 Million USD | -965.044% |
| Affymax, Inc. | -5.59 Million USD | 1327.55% |
| SYBLEU INC | 473.71 Thousand USD | -14403.688% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 10307.565% |
| argenx SE | -2.02 Billion USD | 103.386% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -58.185% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 246.146% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -2436.573% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 877.225% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1263.876% |
| Zenith Capital Corp. | 10.06 Thousand USD | -682590.779% |
| Genscript Biotech Corporation | -1.06 Billion USD | 106.474% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -34178.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -2779.506% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -41664.28% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -13.478% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -3336.345% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 2773.352% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -19000.386% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -238.854% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 375173.698% |
| BioStem Technologies, Inc. | 4.47 Million USD | -1436.356% |
| ONE Bio Corp. | 9.04 Million USD | -660.019% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -34038.949% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 5244832.824% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -33217.331% |
| Agentix Corp. | 37.63 Thousand USD | -182478.194% |
| LadRx Corporation | -2.03 Million USD | 3473.781% |
| Cell Source, Inc. | 9.23 Million USD | -644.218% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 336762.093% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -10716.998% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -10716.998% |
| NovAccess Global Inc. | 2.17 Million USD | -3053.872% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -871.663% |
| Itoco Inc. | 228.3 Thousand USD | -29993.953% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -50423.204% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -1286.04% |
| Kadimastem Ltd | -253.1 Thousand USD | 27245.578% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -16997.467% |
| CytoDyn Inc. | 20.26 Million USD | -239.088% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 10619265.379% |
| Mobile Lads Corp. | 484.23 Thousand USD | -14088.653% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 741397.794% |
| Qrons Inc. | 351.42 Thousand USD | -19450.575% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -791.591% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 27624.237% |
| Rebus Holdings, Inc. | 305 Thousand USD | -22426.557% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -1441.523% |
| International Stem Cell Corporation | 2.59 Million USD | -2552.741% |
| Bioxytran, Inc. | 1.89 Million USD | -3518.173% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -109982.835% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -3050.351% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1900.757% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -703.297% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -8792.749% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 5596.48% |
| Neutra Corp. | 52.18 Thousand USD | -131553.477% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 2860.386% |
| PureTech Health plc | -167.19 Million USD | 141.093% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 28153.8% |
| IXICO plc | -4.44 Million USD | 1645.835% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -419.752% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -25.259% |
| CSL Limited | 10.52 Billion USD | 99.347% |
| Cellectis S.A. | -43.81 Million USD | 256.795% |